Gastroesophageal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastric Adenocarcinoma (40)

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastric Adenocarcinoma (40)

›

HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
HER-2 amplification	Gastroesophageal Cancer	HER-2 amplification	Gastroesophageal Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab + trastuzumab Sensitive: C1 - Off-label pembrolizumab + trastuzumab Sensitive : C1	pembrolizumab + trastuzumab Sensitive: C1 - Off-label pembrolizumab + trastuzumab Sensitive : C1
FGFR2 amplification	Gastroesophageal Cancer	FGFR2 amplification	Gastroesophageal Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
TP53 mutation	Gastroesophageal Cancer	TP53 mutation	Gastroesophageal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
TET1 mutation	Gastroesophageal Cancer	TET1 mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ZW25 Sensitive : C3	ZW25 Sensitive: C3 – Early Trials ZW25 Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HER-2 overexpression	Gastroesophageal Cancer	HER-2 overexpression	Gastroesophageal Cancer	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3	disitamab vedotin Sensitive: C3 – Early Trials disitamab vedotin Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3
MET amplification	Gastroesophageal Cancer	MET amplification	Gastroesophageal Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
TGFB1 elevation	Gastroesophageal Cancer	TGFB1 elevation	Gastroesophageal Cancer	M7824 Sensitive: C3 – Early Trials M7824 Sensitive : C3	M7824 Sensitive: C3 – Early Trials M7824 Sensitive : C3
HER-2 overexpression	Gastroesophageal Cancer	HER-2 overexpression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ZW25 Sensitive : C3	ZW25 Sensitive: C3 – Early Trials ZW25 Sensitive : C3
MET amplification	Gastroesophageal Cancer	MET amplification	Gastroesophageal Cancer	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3
EGFR amplification + ERBB2 amplification	Gastroesophageal Cancer	EGFR amplification + ERBB2 amplification	Gastroesophageal Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
CFB overexpression	Gastroesophageal Cancer	CFB overexpression	Gastroesophageal Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
VEGFC elevation	Gastroesophageal Cancer	VEGFC elevation	Gastroesophageal Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab + margetuximab-cmkb Sensitive: C3 – Early Trials pembrolizumab + margetuximab-cmkb Sensitive : C3	pembrolizumab + margetuximab-cmkb Sensitive: C3 – Early Trials pembrolizumab + margetuximab-cmkb Sensitive : C3
POLE mutation	Gastroesophageal Cancer	POLE mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
POLD1 mutation	Gastroesophageal Cancer	POLD1 mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-L1 expression	Gastroesophageal Cancer	PD-L1 expression	Gastroesophageal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
HER-2 positive + HER-2 amplification	Gastroesophageal Cancer	HER-2 positive + HER-2 amplification	Gastroesophageal Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
CTAG1A expression	Gastroesophageal Cancer	CTAG1A expression	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	margetuximab-cmkb + retifanlimab-dlwr Sensitive: C3 – Early Trials margetuximab-cmkb + retifanlimab-dlwr Sensitive : C3	margetuximab-cmkb + retifanlimab-dlwr Sensitive: C3 – Early Trials margetuximab-cmkb + retifanlimab-dlwr Sensitive : C3
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	trastuzumab + ramucirumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + ramucirumab + tucatinib Sensitive : C3	trastuzumab + ramucirumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + ramucirumab + tucatinib Sensitive : C3
CLDN18.2 expression	Gastroesophageal Cancer	CLDN18.2 expression	Gastroesophageal Cancer	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3
HER-2 mutation	Gastroesophageal Cancer	HER-2 mutation	Gastroesophageal Cancer	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D

Gastroesophageal Cancer

Associations(41)

Associations
(41)